The proposed mechanism of GHK-Cu, the molecular targets implicated, and which steps are demonstrated rather than inferred.
GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine. The proposed mechanism starts from chemistry: the GHK tripeptide binds copper(II) tightly, and the question is what that binding does once the complex meets cells. Two ideas run through the literature. One is that GHK acts as a carrier that delivers copper into cells. The other is that the complex acts as a signalling molecule that changes gene expression and cell behaviour. The published work does not settle which, or whether both are true.
What the compound is and how it is classified is on the GHK-Cu identity page. The literature as a whole is reviewed by evidence tier in the GHK-Cu research review. This page is only about how it is proposed to work.
There is no single established receptor for GHK-Cu. The targets below are of two kinds: a metal-binding site, which is chemistry, and candidate protein targets, which are single-study proposals.
Structural work using X-ray crystallography, EPR, NMR and X-ray absorption spectroscopy (Hureau and colleagues, 2011) shows copper(II) held by the amino group, a deprotonated amide nitrogen and the imidazole nitrogen of the histidine. In solution the complex is a monomer with a labile fourth coordination site, which a carboxylate oxygen occupies in the solid state. Under moderate redox conditions it is inert, but it can be reduced to copper(I) at about −0.62 V against Ag/AgCl, after which copper is released.
The earlier biological observation (Pickart and colleagues, Nature, 1980) is that the tripeptide forms complexes with copper(II) and enhanced copper uptake into cultured hepatoma cells. The authors drew the parallel with copper-transport sites on albumin and alpha-fetoprotein, and proposed a transport role.
| Candidate | System | Basis |
|---|---|---|
| SIRT1 | C2C12 muscle cells and mice exposed to cigarette smoke (2023) | Reported binding and activation, with a computed docking energy of −6.1 kcal/mol |
| SIRT1 and STAT3 signalling | Mice with chemically induced colitis and a mouse cell co-culture (2025) | Target predicted by network pharmacology and docking, then probed by protein expression and gene silencing |
| Peroxiredoxin 6 | Mice with silica-induced lung inflammation and a macrophage cell line (2024) | Reported to bind the protein |
All three are cell or mouse systems, and each comes from a single group using an induced-disease model. SIRT1 recurs, which is interesting, but docking energies and expression changes are suggestive rather than proof of a binding site, and none has been independently replicated in the sources cited here.
A separate line of work uses gene-expression databases to ask which genes the tripeptide is associated with. That is a computational association, reported by authors who work for a skin-biology company (Pickart and Margolina, 2018), and it does not identify a molecular target.
| Statement | Evidence tier | Status |
|---|---|---|
| GHK binds copper(II), with defined coordination geometry | Chemistry, in solution and solid state | Demonstrated |
| The complex can be reduced to copper(I) with release of copper | Chemistry, electrochemical | Demonstrated under the conditions tested |
| GHK enhances copper uptake into cultured cells | In vitro, hepatoma cells, 1980 | Reported, single system |
| The complex stimulates collagen synthesis in fibroblast cultures | In vitro, 1988 | Reported, effect seen from about 10⁻¹² M and maximal near 10⁻⁹ M |
| GHK-Cu binds and activates SIRT1 | Cell and mouse, with docking | Proposed, single group |
| GHK-Cu acts through a defined pathway in human tissue | Human | Not established |
The last row is the honest summary. The mechanism has been described in tubes, dishes and mice, and there is no human study that tests it.
Free GHK without copper is a tripeptide with a copper-binding site. With copper bound it is a metal complex with its own geometry and redox behaviour. Whether biological effects reported for the complex are due to the peptide, the copper, or the combination is not separated by most of the literature, because most studies use the complex and do not run a copper-free control.
Copper(II) complexes are typically coloured, usually blue to violet, because of electronic transitions of the metal ion in its coordination environment. That is a property of the chemistry. It is not a test of identity or purity, and colour alone cannot tell a reader which peptide is bound to the copper. Identity is established by a batch certificate.
The contrast is in molecular architecture, not in a product comparison.
| Compound | What it is | Metal binding |
|---|---|---|
| GHK-Cu | Three-residue peptide, supplied as its copper(II) complex | Defining feature |
| AHK-Cu | Copper complex of a different tripeptide, alanyl-L-histidyl-L-lysine | Also copper-binding, different peptide |
| BPC-157 | Synthetic 15-residue peptide | Not a metal complex |
| TB-500 | Synthetic fragment of thymosin beta-4 | Not a metal complex |
"Copper peptide" is a class name, not a compound. Evidence for one copper-binding peptide does not transfer to another. GHK-Cu is also one of the four components of the KLOW research blend, where it is quantified separately from the other three.
The product record lists batch 100238 with an HPLC purity of 99.843%. Its certificate states the GHK-Cu content and the copper fraction separately, which matters here because the copper is part of the identity of the molecule. It reports the measured composition of that batch and nothing about biological activity, and it does not extend to other batches. The GHK-Cu 50mg product page carries the catalogue record, and the guides to reading a peptide COA and understanding HPLC purity explain what these documents can and cannot show.
Materials sold on this site are supplied solely for non-clinical in-vitro laboratory research. They must not be ingested, injected, inhaled, applied or otherwise administered to a human or animal.
We do not provide dosing, routes of administration, treatment guidance, cosmetic-use guidance or in-vivo protocols. Preparation, storage and handling must follow a validated institutional SOP, the material documentation and an appropriate risk assessment.
An evidence-tiered review of the GHK-Cu literature: in-vitro, animal and human findings, who produced them, and what cannot be concluded from them.
Research DocumentationWhat GHK-Cu is, how copper binds to the GHK tripeptide, how it is classified, and what published research does and does not establish.
Site materials are supplied solely for non-clinical in-vitro laboratory research. They must not be used in or on humans or animals. We do not provide dosing, routes of administration, treatment, cosmetic-use or in-vivo guidance. Read the legal and research-use terms.